Advertisement

2016 ASH Annual Meeting & Exposition

Hematologic Malignancies

Pacritinib Reduces Spleen Volume in Myelofibrosis

The investigational drug pacritinib met the primary endpoint of the phase III PERSIST-2 trial in high-risk patients with myelofibrosis and thrombocytopenia. Treatment with the Janus kinase (JAK)1/2 in...

Multiple Myeloma

CAR T-Cell Therapy Emerging in Multiple Myeloma

For patients with multiple myeloma, chimeric antigen receptor (CAR) T-cell therapy is gaining ground in pilot studies. At the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition,...

Selected Abstracts From the 2016 ASH Annual Meeting

Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in high-grade, aggressive...

Myelodysplastic Syndromes

Expert Point of View: Steven D. Gore, MD, and Rami Komrokji, MD

Steven D. Gore, MD, Director of Hematologic Malignancies at Yale School of Medicine, New Haven, Connecticut, applauded Dr. Stein for “accruing a terrible patient population, mutation-wise” and called...

Myelodysplastic Syndromes

Early Success Reported With Two New Agents for High-Risk Myelodysplastic Syndromes

At the 2016 American Society for Hematology (ASH) Annual Meeting & Exposition, researchers reported early success with two new experimental agents for high-risk myelodysplastic syndromes—enasideni...

Selected Abstracts From the 2016 ASH Annual Meeting

Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in several different type...

Lymphoma

Expert Point of View: Stephen Ansell, MD, PhD

Stephen Ansell, MD, PhD, Chair of the Mayo Clinic Lymphoma Group, said the “exciting results” of these studies indicated that “we have come a long way in Hodgkin lymphoma.” “It’s been very gratifying...

Lymphoma

Studies Advance the Use of PD-1 Blockade in Classical Hodgkin Lymphoma

Classical Hodgkin lymphoma is one of the malignancies most susceptible to treatment with monoclonal antibodies targeting the programmed cell death protein (PD-1). Nivolumab (Opdivo) has been approved ...

Hematologic Malignancies
Symptom Management

Expert Point of View: Kanti R. Rai, MD

Kanti R. Rai, MD, Professor of Medicine, Hofstra Northwell School of Medicine, New Hyde Park, New York, commented on these study findings. “I congratulate the investigators for a work done with disci...

Hematologic Malignancies
Symptom Management

Ibrutinib: A Potential Option for Chronic Graft-vs-Host Disease?

Currently, there is no U.S. Food and Drug Administration (FDA)-approved therapy for chronic graft-vs-host disease—a life-threatening consequence of stem cell or bone marrow transplant—that has not re...

Lymphoma

Selected Abstracts From the 2016 ASH Annual Meeting

Here are several abstracts selected from the proceedings of this year’s American Society of Hematology (ASH) Annual Meeting & Exposition, highlighting newer therapeutics in follicular lymphoma. F...

Multiple Myeloma

Antiretroviral Agent Makes Strong Showing in Refractory Multiple Myeloma

An antiretroviral drug that is used for human immunodeficiency virus (HIV) demonstrated strong activity when combined with bortezomib (Velcade) in patients with relapsed/refractory multiple myeloma i...

Lymphoma

Expert Point of View: Anas Younes, MD

Anas Younes, MD, Chief of the Lymphoma Service at Memorial Sloan Kettering Cancer Center, New York, commented on the brentuximab vedotin (Adcetris)/nivolumab (Opdivo) combination studies, noting that...

Lymphoma

Brentuximab Vedotin Plus Nivolumab Highly Active in Relapsed Classical Hodgkin Lymphoma

Response rates of 90% to 100% were achieved in early studies evaluating the combination of brentuximab vedotin (Adcetris) and nivolumab (Opdivo) in relapsed or refractory classical Hodgkin lymphoma. ...

Lymphoma

CAR T-Cell Therapy KTE-C19 Appears Successful in Aggressive B-Cell Lymphoma

Chimeric antigen receptor (CAR) T-cell therapy continues to have impressive showings in patients with aggressive hematologic malignancies and no other good treatment options. Interim results of the pi...

Multiple Myeloma

Expert Point of View: Philip ­McCarthy, MD

The ASCO Post asked Philip ­McCarthy, MD, Professor of Oncology and Internal Medicine at Roswell Park Cancer, Buffalo, and Director of the Blood and Marrow Transplant Center there, to comment on thes...

Multiple Myeloma

High Response Rates to Triplet Therapy in Smoldering Myeloma

High-risk patients with smoldering multiple myeloma responded to a regimen of elotuzumab (Empliciti), lenalidomide (Revlimid), and dexamethasone, in a multicenter phase II study led by Irene Ghobrial...

Leukemia

Expert Point of View: Richard Furman, MD

“These results are interesting, important, and relevant for maintenance post chemotherapy, but if we are not using chemotherapy, they may not be relevant,” said Richard Furman, MD, of Weill Cornell M...

Leukemia

Lenalidomide Maintenance Extends Progression-Free Survival in CLL

Lenalidomide (Revlimid), a cornerstone of therapy for multiple myeloma in the modern era, is making headway as maintenance therapy in chronic lymphocytic leukemia (CLL). Separate phase III studies pre...

Leukemia

Expert Point of View: Armand Keating, MD

“This study shows that a great deal of innovation can come from existing knowledge. The 7+3 regimen has been around since I was an intern,” admitted Armand Keating, MD, of the University of Toronto a...

Leukemia

CPX-351 Improves Survival Post Transplant in Older High-Risk Patients With Acute Myeloid Leukemia

Induction therapy with the experimental chemotherapy called CPX-351—a liposomal formulation of cytarabine and daunorubicin—outperformed standard “7+3” cytarabine plus daunorubicin by extending surviva...

Leukemia

Expert Point of View: Mikkael A. Sekeres, MD, MS

Mikkael A. Sekeres, MD, MS, Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Center in Ohio, commented on vadastuximab talirine in newly diagnosed acute myeloid leukemia (AML)....

Leukemia

Vadastuximab Talirine Shows Early Promise in Newly Diagnosed Acute Myeloid Leukemia

The investigational CD33-directed antibody-drug conjugate vadastuximab talirine yielded high overall and complete response rates when combined with standard “7+3” chemotherapy for patients newly diag...

Lymphoma

Expert Point of View: Lawrence Kaplan, MD

“This study is important because R-CHOP [rituximab and cyclophosphamide, doxorubicin, vincristine, prednisone] has been the standard of care for many years. CHOP, the chemotherapy backbone, has withs...

Lymphoma

Dose-Adjusted EPOCH-R No Better Than R-CHOP in Diffuse Large B-Cell Lymphoma

Long-awaited results of the Cancer and Leukemia Group B ­(CALGB)/Alliance 50303 trial were a disappointment to many hematologists/oncologists at the 2016 American Society of Hematology (ASH) Annual Me...

Lymphoma

Expert Point of View: Brad S. Kahl, MD

Speaking about the GALLIUM study in the ASH News Daily, Brad S. Kahl, MD, of Washington University School of Medicine, St. Louis, commented, “It is a potentially practice-changing study that clearly ...

Lymphoma

Obinutuzumab Prolongs Disease-Free Survival vs Rituximab in Follicular Lymphoma

Induction and maintenance therapies with obinutuzumab (Gazyva) were superior to rituximab (Rituxan) induction and maintenance in patients with untreated follicular lymphoma, according to results of th...

Multiple Myeloma

Expert Point of View: Sergio A. Giralt, MD

Sergio A. Giralt, MD, Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, New York, and the Melvin Berlin Family Chair in Multiple Myeloma, commented on the f...

Multiple Myeloma

Single Autotransplant Not Enhanced by Additional Interventions in Multiple Myeloma

Additional interventions following upfront autologous stem cell transplant in multiple myeloma did not further improve progression-free or overall survival over transplant alone in a multicenter study...

Individuals Honored as 2016 MPN Heroes

Eight individuals were honored at the 2016 MPN Heroes celebration held on the eve of the American Society of Hematology’s (ASH) Annual Meeting & Exposition in San Diego. The MPN Hero award is give...

Leukemia

Expert Point of View: Amir T. Fathi, MD

“In the past few years, there has been increased reporting of other, less traditional, response criteria in acute myeloid leukemia (AML), including morphologic leukemia-free state, partial response, ...

Leukemia

Achieving Complete Response Is Key to Improving Survival in Older Patients With AML

The importance of achieving complete response after intensive therapy in older adults with acute myeloid leukemia (AML) was confirmed in a follow-up analysis of the E2906 North American Intergroup tri...

Leukemia

Expert Point of View: Mikkael Sekeres, MD

In his practice, Mikkael Sekeres, MD, of the Cleveland Clinic Foundation, has not initiated dose reductions of tyrosine kinase inhibitors, but “anecdotally, my patients tell me that they have reduced...

Leukemia

Reducing Doses and Stopping Tyrosine Kinase Inhibitors Gain Favor in Chronic Myeloid Leukemia

Tyrosine kinase inhibitors, such as imatinib, nilotinib (Tasigna), and dasatinib (Sprycel), have revolutionized the treatment of chronic myeloid leukemia (CML). A substantial percentage of patients ac...

Leukemia

Expert Point of View: Stephen P. Hunger, MD

Stephen P. Hunger, MD, Chief of the Division of Pediatric Oncology and Director of the Center for Childhood Cancer Research at The Children’s Hospital of Philadelphia, and the Jeffrey E. Perelman Dis...

Leukemia

Reduced-Intensity Chemotherapy Leads to More Relapses in Childhood ALL

Children with acute lymphoblastic leukemia (ALL) considered at standard risk for relapse should continue to receive standard-intensity regimens, according to findings from the international randomized...

Lymphoma

‘Clinically Useful’ Findings for Brentuximab Vedotin in CTCL, Rituximab Maintenance in MCL

Positive studies about brentuximab vedotin ­(Adcetris) in cutaneous T-cell lymphoma1 and rituximab (Rituxan) maintenance therapy in mantle cell lymphoma (MCL)2 were reported at the 2016 Annual Meeting...

leukemia

Martin Schrappe, MD, on Childhood ALL: Study Results on Reducing Treatment Burden (German Language Version)

Martin Schrappe, MD, of Christian-Albrechts University Kiel, discusses in German study findings on reduced intensity delayed intensification in standard-risk patients defined by minimal residual disea...

lymphoma

Robert E. Marcus, MD, on Follicular Lymphoma: Results From the GALLIUM Trial

Robert E. Marcus, MD, of Kings College Hospital, discusses study findings on obinutuzumab-based induction and maintenance in patients with previously untreated disease (Abstract 6).

leukemia

Julie Vose, MD, MBA, and Anjali Advani, MD, on AML: Results of Two Trials on Vadastuximab Talirine

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Anjali Advani, MD, of the Cleveland Clinic, discuss study findings on vadastuximab talirine as monotherapy and, in another trial,...

leukemia

Julie Vose, MD, MBA, and Mhairi Copland, MB, ChB, PhD, on CML: Data From the British DESTINY Study

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Mhairi Copland, MB, ChB, PhD, of the Paul O’Gorman Leukaemia Research Centre at the University of Glasgow, discuss decreasing the...

leukemia

Harry P. Erba, MD, PhD, on AML: Early Study Results on Vadastuximab Talirine

Harry P. Erba, MD, PhD, of the University of Alabama at Birmingham, discusses phase Ib findings on vadastuximab talirine in combination with 7+3 induction therapy for patients with newly diagnosed AML...

leukemia

Jeffrey E. Lancet, MD, on AML: Subgroup Analysis of a Phase III Trial

Jeffrey E. Lancet, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses study findings on survival following allogeneic hematopoietic cell transplantation in older, high-risk acut...

Stephen M. Ansell, MD, PhD, on Hematologic Malignancies: Results of the CheckMate 039 Trial

Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses phase I study findings on nivolumab in combination with ipilimumab for relapsed or refractory disease (Abstract 183).

leukemia

Terry J. Fry, MD, on ALL: MRD and CAR Therapy

Terry J. Fry, MD, of the Pediatric Oncology Branch of the National Cancer Institute, discusses minimal residual disease–negative complete remissions following anti-CD22 chimeric antigen receptor in ch...

leukemia

Martin Schrappe, MD, on Childhood ALL: Study Results on Reducing Treatment Burden

Martin Schrappe, MD, of Christian-Albrechts University Kiel, discusses study findings on reduced intensity delayed intensification in standard-risk patients defined by minimal residual disease in chil...

lymphoma

Steven Le Gouill, MD, PhD, on Mantle Cell Lymphoma: Final Results From the LyMa Trial (French Language Version)

Steven Le Gouill, MD, PhD, of Nantes University Hospital and INSERM, discusses in French study findings from the Lysa/Goelams Group on rituximab maintenance after autologous stem cell transplantation ...

lymphoma

Catherine Thieblemont, MD, PhD, on DLBCL: Results From the Lysa Remarc Study (French Language Version)

Catherine Thieblemont, MD, PhD, of Hôpital Saint-Louis and INSERM, discusses in French phase III trial findings on lenalidomide maintenance in elderly patients with DLBCL treated with R-CHOP in the fi...

lymphoma

Steven Le Gouill, MD, PhD, on Mantle Cell Lymphoma: Final Results From the LyMa Trial

Steven Le Gouill, MD, PhD, of Nantes University Hospital and INSERM, discusses study findings from the Lysa/Goelams Group on rituximab maintenance after autologous stem cell transplantation in younger...

hematologic malignancies
issues in oncology

Marie Bleakley, MD, PhD, on GVHD: Reducing Rates and Increasing Survival

Marie Bleakley, MD, PhD, of Fred Hutchinson Cancer Research Center, discusses data on using naive T-cell depletion of peripheral blood stem cells, which led to very low rates of chronic graft-vs-host-...

Advertisement

Advertisement



Advertisement

click me